Skip to main content

AbilityPharma: Accelerating Solutions for Pancreatic Cancer

Project description

New drug for the treatment of pancreatic cancer

ABTL0812 is a first-in-class oral targeted anticancer compound developed by Ability Pharmaceuticals, that produces autophagy-mediated cytotoxicity in cancer cells. In preclinical studies, ABTL0812 showed efficacy as a single agent and in combination with standard-of-care treatments in in vitro and in animal models of pancreatic cancer, a disease with an unmet clinical need for new therapies. It induced tumor regression without increasing the toxicity associated with chemotherapy and demonstrated safety and well-tolerated toxicities in the first-in-human phase 1/1b clinical trial. In a phase 1/2a clinical trial in endometrial and lung cancer patients, ABTL0812, in combination with the standard-of-care chemotherapy, demonstrated superiority over chemotherapy alone. The EU-funded PanC-ASAP project will start a phase 2 clinical trial in pancreatic cancer to investigate the new drug in combination with the standard-of-care chemotherapy.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-EIC-SMEInst-2018-2020-3

Coordinator

ABILITY PHARMACEUTICALS SL
Net EU contribution
€ 2 325 865,38
Address
Edifici Eureka - Campus De La Uab
08193 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 2 325 865,38